by Anthony L. Vaccarino, PhD; Kenneth R. Evans, PhD; Amir H. Kalali, MD; Sidney H. Kennedy, MD, FRCPC; Nina Engelhardt, PhD; Benico N. Frey, MD, MSc, PhD; John H. Greist,
by J. Gibson Pennington, MD, and Jeffrey Guina, MD From Wright-Patterson Air Force Base and Wright State University Boonshoft School of Medicine Department of Psychiatry, Dayton, Ohio Innov Clin Neurosci.
by Jonathan R. Scarff, MD Dr. Scarff is a staff psychiatrist at the Veterans Affairs Outpatient Clinic in Spartanburg, South Carolina, USA Innov Clin Neurosci. 2016;13(9–10):49–52 Funding: The author has
by Ann McNary, JD Ms. McNary is Senior Risk Manager at PRMS, Inc. in Arlington, Virginia. Innov Clin Neurosci. 2016;13(9–10)53–55. This ongoing column is dedicated to providing information to our
by Steven Lippmann, MD, and Malathi Latha Perugula, MD The authors are from the Department of Psychiatry and Behavioral Science, University of Louisville School of Medicine, Louisville, Kentucky. Innov Clin
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie
by Jonathan R. Scarff, MD Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2016;13(7–8):26–29. Funding: No funding was received for the preparation of this
by Ram S. Mahato, MD; Maria Chona P. San Gabriel, MD; Carrol T. Longshore, MD; and David B. Schnur, MD The authors are with the Department of Psychiatry at Elmhurst
by Donna Vanderpool, MBA, JD Ms. Vanderpool is Vice President of Risk Management at PRMS, Inc., Arlington, Virginia. Innov Clin Neurosci. 2016;13(7–8):41–44. This ongoing column is dedicated to providing information
Innov Clin Neurosci. 2016;13(7–8):15–16. Dear Editor: Borderline personality disorder (BPD) is over-represented in prison populations, with 25 to 50 percent of incarcerated individuals suffering from this disorder.[1] As an empirical
Innov Clin Neurosci. 2016;13(7–8):13–14. Dear Editor: Substance use disorders frequently coexist with and complicate the treatment of mood and anxiety disorders. Gabapentin is one of the most commonly prescribed off-label
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to
by Arshya Vahabzadeh, MD; Ned Sahin, PhD; and Amir Kalali, MD Dr. Vahabzadeh is Director of Digital Health, Brain Power, in Cambridge, Massachusetts; Instructor in Psychiatry, Harvard Medical School in
by Kimberly B. Mulcahy, PharmD; Eileen Trigoboff, RN, DNS; Lewis Opler, MD, PhD; and Tammie Lee Demler, BS, PharmD, MBA Drs. Trigoboff, Demler, and Mulcahy are with Buffalo Psychiatric Center,
